Visual Podcast: Expert Tips For Staving Off De Novo Troubles
This article was originally published in The Gray Sheet
Executive Summary
King & Spalding's Quynh Hoang offers device manufacturers a handful of tips for pursuing de novo classification submissions – including urging firms to determine whether clinical studies are needed for a potential de novo submission – in this "Gray Sheet" podcast.
You may also be interested in...
Successful De Novo Petitions Double With Advent Of Direct Route
FDA granted more than double the number of de novo petitions in FY 2013 compared to past years, reflecting the availability of the direct de novo pathway recently established by Congress. De novo petitions allow a device that FDA deems to be low-to-moderate risk but without a clear predicate to enter the market without requiring a PMA.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.